Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers.: CYCLON-induced Rituximab resistance

Abstract : Immuno-chemotherapy elicit high response rates in B-cell non-Hodgkin lymphoma but heterogeneity in response duration is observed, with some patients achieving cure and others showing refractory disease or relapse. Using a transcriptome-powered targeted proteomics screen, we discovered a gene regulatory circuit involving the nuclear factor CYCLON which characterizes aggressive disease and resistance to the anti-CD20 monoclonal antibody, Rituximab, in high-risk B-cell lymphoma. CYCLON knockdown was found to inhibit the aggressivity of MYC-overexpressing tumours in mice and to modulate gene expression programs of biological relevance to lymphoma. Furthermore, CYCLON knockdown increased the sensitivity of human lymphoma B cells to Rituximab in vitro and in vivo. Strikingly, this effect could be mimicked by in vitro treatment of lymphoma B cells with a small molecule inhibitor for BET bromodomain proteins (JQ1). In summary, this work has identified CYCLON as a new MYC cooperating factor that autonomously drives aggressive tumour growth and Rituximab resistance in lymphoma. This resistance mechanism is amenable to next-generation epigenetic therapy by BET bromodomain inhibition, thereby providing a new combination therapy rationale for high-risk lymphoma.
Type de document :
Article dans une revue
EMBO Molecular Medicine, Wiley Open Access, 2013, 5 (8), pp.1180-95. 〈10.1002/emmm.201202034〉
Liste complète des métadonnées

Littérature citée [65 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00852222
Contributeur : Samuel Duley <>
Soumis le : mardi 20 août 2013 - 11:55:25
Dernière modification le : jeudi 28 juin 2018 - 09:50:58
Document(s) archivé(s) le : jeudi 21 novembre 2013 - 04:14:00

Fichier

emmm201202034.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Collections

Citation

Anouk Emadali, Sophie Rousseaux, Juliana Bruder-Costa, Claire Rome, Samuel Duley, et al.. Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers.: CYCLON-induced Rituximab resistance. EMBO Molecular Medicine, Wiley Open Access, 2013, 5 (8), pp.1180-95. 〈10.1002/emmm.201202034〉. 〈inserm-00852222〉

Partager

Métriques

Consultations de la notice

1099

Téléchargements de fichiers

393